Literature DB >> 8188650

An SH3 domain and proline-rich sequence mediate an interaction between two components of the phagocyte NADPH oxidase complex.

P Finan1, Y Shimizu, I Gout, J Hsuan, O Truong, C Butcher, P Bennett, M D Waterfield, S Kellie.   

Abstract

Neutrophils possess a multicomponent NADPH oxidase system capable of producing large quantities of superoxide in a process known as the respiratory burst (1). Upon stimulation of a phagocytic cell, two cytosolic components of the oxidase, p67phox and p47phox, associate with a membrane-bound flavocytochrome b and a small GTP-binding protein to form a functional enzyme complex. Each of the Phox proteins contains two src homology 3 (SH3) domains, which are of unknown function but are potential mediators of protein-protein interactions between components of the activated oxidase. We have isolated a 47-kDa protein from lysates of differentiated HL60 cells that specifically bound to the carboxyl-terminal SH3 domain of p67phox and not to any other SH3 domain tested. This protein was identified as p47phox, and the putative SH3 domain binding site was located to a carboxyl-terminal proline-rich region. Proline-rich synthetic peptides based on this carboxyl-terminal region specifically inhibited the binding of p47phox to the carboxyl-terminal SH3 domain of p67phox, and sequential truncation defined a unique minimal sequence, which, although similar, does not match the consensus sequence defined for other SH3-binding proteins.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8188650

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

Review 1.  Protein-protein interactions in signaling cascades.

Authors:  B J Mayer
Journal:  Mol Biotechnol       Date:  1999-12-15       Impact factor: 2.695

2.  Activation state-dependent interaction between Galphai and p67phox.

Authors:  Caroline Marty; Tohru Kozasa; Mark T Quinn; Richard D Ye
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

3.  PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47 phox.

Authors:  J Shi; C R Ross; T L Leto; F Blecha
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

Review 4.  Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system.

Authors:  Bernard Lassègue; Alejandra San Martín; Kathy K Griendling
Journal:  Circ Res       Date:  2012-05-11       Impact factor: 17.367

5.  Multiple SH3 domain interactions regulate NADPH oxidase assembly in whole cells.

Authors:  I de Mendez; A G Adams; R A Sokolic; H L Malech; T L Leto
Journal:  EMBO J       Date:  1996-03-15       Impact factor: 11.598

6.  Distinct ligand preferences of Src homology 3 domains from Src, Yes, Abl, Cortactin, p53bp2, PLCgamma, Crk, and Grb2.

Authors:  A B Sparks; J E Rider; N G Hoffman; D M Fowlkes; L A Quillam; B K Kay
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

7.  Interactions between cytosolic components of the NADPH oxidase: p40phox interacts with both p67phox and p47phox.

Authors:  F B Wientjes; G Panayotou; E Reeves; A W Segal
Journal:  Biochem J       Date:  1996-08-01       Impact factor: 3.857

Review 8.  NADPH oxidases: an overview from structure to innate immunity-associated pathologies.

Authors:  Arvind Panday; Malaya K Sahoo; Diana Osorio; Sanjay Batra
Journal:  Cell Mol Immunol       Date:  2014-09-29       Impact factor: 11.530

9.  Diverse recognition of non-PxxP peptide ligands by the SH3 domains from p67(phox), Grb2 and Pex13p.

Authors:  Keiichiro Kami; Ryu Takeya; Hideki Sumimoto; Daisuke Kohda
Journal:  EMBO J       Date:  2002-08-15       Impact factor: 11.598

10.  Tyrosine phosphatase antagonist-induced activation of the neutrophil NADPH oxidase: a possible role for protein kinase C.

Authors:  P A Bennett; P M Finan; R J Dixon; S Kellie
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.